Induction of pluripotency by defined factors
Koji Tanabe1, Kazutoshi Takahashi, Shinya Yamanaka
1Center for iPS Cell Research and Application (CiRA), Kyoto University.
Summary
Scientists converted somatic cells into pluripotent stem cells using defined factors. These induced pluripotent stem (iPS) cells offer new possibilities for regenerative medicine and drug discovery.
Area of Science:
- Cell biology
- Stem cell research
- Developmental biology
Background:
- Reversing cell fate to totipotent or pluripotent states has long been a scientific goal.
- Somatic cells are specialized cells with limited differentiation potential.
Purpose of the Study:
- To investigate the possibility of reprogramming somatic cells into a pluripotent state.
- To generate induced pluripotent stem (iPS) cells from somatic cells.
Main Methods:
- Forced expression of specific reprogramming factors in somatic cells.
- Culture and characterization of the resulting stem cells.
Main Results:
- Successfully converted somatic cells into a pluripotent cell lineage.
- Generated induced pluripotent stem (iPS) cells exhibiting pluripotency and immortality.
- iPS cells share key characteristics with embryonic stem (ES) cells.
Conclusions:
- Induced pluripotent stem (iPS) cell technology is achievable through forced expression of defined factors.
- iPS cells hold significant promise for applications in regenerative medicine.
- This technology opens new avenues for drug discovery and disease modeling.
More Related Videos
Related Concept Videos
01:13Induced Pluripotent Stem Cells
22.9K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
22.9K
01:06Induced Pluripotent Stem Cells
4.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.8K
01:13Induced Pluripotent Stem Cells
3.4K
3.4K
01:29Somatic to iPS Cell Reprogramming
2.1K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.1K
01:22iPS Cell Differentiation
2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K
01:24Methods of Nuclear Reprogramming
1.4K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.4K